Search research articles
Contact Us
Filters
Showing results (121-130 of 338) with videos related to
Page
of 34
Sort By:
Cancer
|
September 4, 2009
Results of a multicenter, randomized, double-blind, dose-evaluating phase 2/3 study of lenalidomide in the treatment of metastatic malignant melanoma
John Glaspy, Michael B Atkins, Jon M Richards, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
April 4, 2007
Angiopoietin 2 is a potential mediator of high-dose interleukin 2-induced vascular leak
Diana C Gallagher, Rupal S Bhatt, Samir M Parikh, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
November 13, 2008
Phase III trial comparing concurrent biochemotherapy with cisplatin, vinblastine, dacarbazine, interleukin-2, and interferon alfa-2b with cisplatin, vinblastine, and dacarbazine alone in patients with metastatic malignant melanoma (E3695): a trial coordinated by the Eastern Cooperative Oncology Group
Michael B Atkins, Jessie Hsu, Sandra Lee, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
October 11, 2002
A phase II pilot trial of concurrent biochemotherapy with cisplatin, vinblastine, temozolomide, interleukin 2, and IFN-alpha 2B in patients with metastatic melanoma
Michael B Atkins, Jared A Gollob, Jeffrey A Sosman, et al.
Journal for Immunotherapy of Cancer
|
January 30, 2026
Partitioned overall survival: comprehensive analysis of survival states over 4 years in CheckMate 9ER comparing first-line nivolumab plus cabozantinib versus sunitinib in advanced renal cell carcinoma
Hollis Viray, Charlene M Mantia, Opeyemi A Jegede, et al.
Journal of Translational Medicine
|
July 31, 2009
Phase I/II open-label study of the biologic effects of the interleukin-2 immunocytokine EMD 273063 (hu14.18-IL2) in patients with metastatic malignant melanoma
Antoni Ribas, John M Kirkwood, Michael B Atkins, et al.
Radiology
|
September 1, 2009
Dynamic contrast-enhanced MR imaging for differentiation of renal cell carcinoma subtypes: myth or reality?
Michele Scialpi, Luca Brunese, Irene Piscioli, et al.
Journal of Immunotherapy (Hagerstown, Md. : 1997)
|
July 27, 2002
Induction of myasthenia gravis, myositis, and insulin-dependent diabetes mellitus by high-dose interleukin-2 in a patient with renal cell cancer
Paula G Fraenkel, Seward B Rutkove, Jean K Matheson, et al.
JAMA Oncology
|
March 10, 2017
Adjuvant Treatment for High-Risk Clear Cell Renal Cancer: Updated Results of a High-Risk Subset of the ASSURE Randomized Trial
Naomi B Haas, Judith Manola, Janice P Dutcher, et al.
Clinical Genitourinary Cancer
|
May 13, 2021
Q-TWiST Analysis of Tivozanib Versus Sorafenib in Patients With Advanced Renal Cell Carcinoma in the TIVO-3 Study
Michael Szarek, Michael N Needle, Brian I Rini, et al.
Page
of 34
Search research articles
Search
Showing results (121-130 of 338) with videos related to
Sort By:
Page
of 34
Cancer
|
September 4, 2009
Results of a multicenter, randomized, double-blind, dose-evaluating phase 2/3 study of lenalidomide in the treatment of metastatic malignant melanoma
John Glaspy, Michael B Atkins, Jon M Richards, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
April 4, 2007
Angiopoietin 2 is a potential mediator of high-dose interleukin 2-induced vascular leak
Diana C Gallagher, Rupal S Bhatt, Samir M Parikh, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
November 13, 2008
Phase III trial comparing concurrent biochemotherapy with cisplatin, vinblastine, dacarbazine, interleukin-2, and interferon alfa-2b with cisplatin, vinblastine, and dacarbazine alone in patients with metastatic malignant melanoma (E3695): a trial coordinated by the Eastern Cooperative Oncology Group
Michael B Atkins, Jessie Hsu, Sandra Lee, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
October 11, 2002
A phase II pilot trial of concurrent biochemotherapy with cisplatin, vinblastine, temozolomide, interleukin 2, and IFN-alpha 2B in patients with metastatic melanoma
Michael B Atkins, Jared A Gollob, Jeffrey A Sosman, et al.
Journal for Immunotherapy of Cancer
|
January 30, 2026
Partitioned overall survival: comprehensive analysis of survival states over 4 years in CheckMate 9ER comparing first-line nivolumab plus cabozantinib versus sunitinib in advanced renal cell carcinoma
Hollis Viray, Charlene M Mantia, Opeyemi A Jegede, et al.
Journal of Translational Medicine
|
July 31, 2009
Phase I/II open-label study of the biologic effects of the interleukin-2 immunocytokine EMD 273063 (hu14.18-IL2) in patients with metastatic malignant melanoma
Antoni Ribas, John M Kirkwood, Michael B Atkins, et al.
Radiology
|
September 1, 2009
Dynamic contrast-enhanced MR imaging for differentiation of renal cell carcinoma subtypes: myth or reality?
Michele Scialpi, Luca Brunese, Irene Piscioli, et al.
Journal of Immunotherapy (Hagerstown, Md. : 1997)
|
July 27, 2002
Induction of myasthenia gravis, myositis, and insulin-dependent diabetes mellitus by high-dose interleukin-2 in a patient with renal cell cancer
Paula G Fraenkel, Seward B Rutkove, Jean K Matheson, et al.
JAMA Oncology
|
March 10, 2017
Adjuvant Treatment for High-Risk Clear Cell Renal Cancer: Updated Results of a High-Risk Subset of the ASSURE Randomized Trial
Naomi B Haas, Judith Manola, Janice P Dutcher, et al.
Clinical Genitourinary Cancer
|
May 13, 2021
Q-TWiST Analysis of Tivozanib Versus Sorafenib in Patients With Advanced Renal Cell Carcinoma in the TIVO-3 Study
Michael Szarek, Michael N Needle, Brian I Rini, et al.
Page
of 34